Savient Pharmaceuticals enjoys increasing revenues

Sales of its intravenous gout drug Krystexxa rose by 30 per cent during the second quarter.

Net sales for one of Savient Pharmaceutical's biggest drugs grew by 30 per cent in the second quarter of 2012, according to the company's latest financials.

Revenue from Krystexxa reached ￡4 million for the second three months of the year, a considerable gain on the first quarter of the year.

Krystexxa is the trade name for pegloticase, an intravenous drug that is used to treat severe cases of chronic gout.

It was approved by the US Food and  Drug Administration in 2010 for marketing following the completion of two clinical trials showing that it can lower uric acid levels in patients with the painful condition.

When there is too much uric acid in the joints and soft tissues, it can crystalise leading to swelling and significant pain.

"We are confident in our plan, which builds upon the foundation we have established and the long term opportunity for Krystexxa," s